News Headlines
-
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
3/18/2024
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318401921/en/ Jennifer Riter joins Kindeva Drug Delivery as Vice President of Analytical Services to lead new analytical services business unit. (Photo: Business Wire) Riter comes to Kindeva from West Pharmaceutical where she
-
Grace Expands Contract Development & Manufacturing Organization Services In South Haven, MI
3/18/2024
W. R. Grace & Co. (Grace), a leading global specialty chemicals company, today announced the opening of its expanded fine chemical contract development and manufacturing (CDM) facility in South Haven, MI. Grace executives and local community leaders joined more than 200 employees at the site for a ribbon cutting to mark completion of the 21-month project.
-
BioPIPS Consortium In Singapore Expands Membership, Seeks To Enhance Productivity And Sustainability In Biologics Manufacturing
3/18/2024
The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium has been expanded with the addition of global immunotherapy company, BioNTech.
-
Applied DNA Enters into Agreement With Alphazyme For Scale-Up Manufacturing Of Its Proprietary Linea RNAP, Progresses Towards GMP Linea IVT Production Start
3/18/2024
Applied DNA Sciences, Inc. (Applied DNA or the Company), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (MRVI) and global provider of specialty enzymes used in the life sciences sector, have entered into an agreement under which Alphazyme will scale-up manufacturing of Applied DNA's proprietary Linea RNA polymerase ("RNAP").
-
Novartis Expands Its Biopharmaceutical Manufacturing Site In Singapore
3/15/2024
Novartis today announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore.
-
Charles River And Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
3/14/2024
Charles River Laboratories International, Inc. and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I clinical trials.
-
Pace Life Sciences Acquires New Jersey Laboratory From Curia
3/14/2024
Pace Life Sciences, LLC, a contract development, and manufacturing organization (CDMO), announced today that it has acquired the Lebanon, New Jersey laboratory facility (formerly Whitehouse Analytical Laboratories) from Curia, a global contract research, development, and manufacturing (CDMO) company.
-
Cellipont Bioservices And Wugen Sign Agreement For The Clinical Manufacture Of Wugen's Off-The-Shelf CAR-T Cellular Therapies
3/14/2024
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.
-
Pluri Selected As CDMO By Remedy Cell For Cell-Derived Cell-Free Drug Manufacturing
3/14/2024
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
-
Noramco Announces Strategic Alignment With Purisys And Halo Pharma, Launching The Noramco Group As An Integrated North American-Based API And Drug Product Supply Chain Services Provider
3/14/2024
Noramco, a leading global active pharmaceutical ingredients manufacturer specializing in controlled substances, today announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.